JP2022547952A - Ｂｒｄ９二機能性分解誘導薬及びその使用方法 - Google Patents

Ｂｒｄ９二機能性分解誘導薬及びその使用方法 Download PDF

Info

Publication number
JP2022547952A
JP2022547952A JP2022515701A JP2022515701A JP2022547952A JP 2022547952 A JP2022547952 A JP 2022547952A JP 2022515701 A JP2022515701 A JP 2022515701A JP 2022515701 A JP2022515701 A JP 2022515701A JP 2022547952 A JP2022547952 A JP 2022547952A
Authority
JP
Japan
Prior art keywords
group
alkyl
formula
alkylene
heteroalkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022515701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547952A5 (https=
Inventor
ローバー，ジュリエン
センジック，マーティン
チェン，シン
グード，マリー－リン
ハリントン，エドマンド，マーティン
ホリングワース，グレゴリー，ジョン
ブルペッティ，アンナ
ゾラー，トーマス
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72915891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2022547952(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2022547952A publication Critical patent/JP2022547952A/ja
Publication of JP2022547952A5 publication Critical patent/JP2022547952A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022515701A 2019-09-16 2020-09-14 Ｂｒｄ９二機能性分解誘導薬及びその使用方法 Pending JP2022547952A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962900869P 2019-09-16 2019-09-16
US201962900865P 2019-09-16 2019-09-16
US201962900863P 2019-09-16 2019-09-16
US201962900860P 2019-09-16 2019-09-16
US62/900,863 2019-09-16
US62/900,860 2019-09-16
US62/900,865 2019-09-16
US62/900,869 2019-09-16
PCT/US2020/050768 WO2021055295A1 (en) 2019-09-16 2020-09-14 Brd9 bifunctional degraders and their methods of use

Publications (2)

Publication Number Publication Date
JP2022547952A true JP2022547952A (ja) 2022-11-16
JP2022547952A5 JP2022547952A5 (https=) 2023-09-25

Family

ID=72915891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515701A Pending JP2022547952A (ja) 2019-09-16 2020-09-14 Ｂｒｄ９二機能性分解誘導薬及びその使用方法

Country Status (21)

Country Link
US (1) US20220315578A1 (https=)
EP (1) EP4041724A1 (https=)
JP (1) JP2022547952A (https=)
KR (1) KR20220063192A (https=)
CN (1) CN114641473A (https=)
AU (1) AU2020349451B2 (https=)
BR (1) BR112022003514A2 (https=)
CA (1) CA3153529A1 (https=)
CO (1) CO2022002842A2 (https=)
CR (1) CR20220105A (https=)
DO (1) DOP2022000053A (https=)
EC (1) ECSP22018571A (https=)
IL (1) IL290677A (https=)
JO (1) JOP20220069A1 (https=)
MX (1) MX2022003102A (https=)
PE (1) PE20221417A1 (https=)
PH (1) PH12022550611A1 (https=)
PY (1) PY2054376A (https=)
TW (1) TW202123942A (https=)
UY (1) UY38880A (https=)
WO (1) WO2021055295A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022547716A (ja) * 2019-09-16 2022-11-15 ノバルティス アーゲー 二機能性分解誘導薬及びそれらの使用方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746135A4 (en) 2018-01-30 2022-03-09 Foghorn Therapeutics Inc. METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE
CN111936498B (zh) 2018-03-26 2024-04-16 诺华股份有限公司 N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
EP3917517A4 (en) 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF
CN113874016A (zh) 2019-01-29 2021-12-31 福宏治疗公司 化合物及其用途
US20230066136A1 (en) 2019-01-29 2023-03-02 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
CR20220160A (es) 2019-09-16 2022-06-16 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
EP4096651A4 (en) * 2020-01-29 2024-01-24 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
US12528825B2 (en) 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
TW202146412A (zh) 2020-03-05 2021-12-16 美商Ｃ４醫藥公司 用於標靶降解brd9之化合物
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
US11767330B2 (en) 2021-07-06 2023-09-26 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
WO2023039208A1 (en) * 2021-09-09 2023-03-16 C4 Therapeutics, Inc. Selected compounds for targeted degradation of brd9
WO2023109892A1 (zh) * 2021-12-15 2023-06-22 海思科医药集团股份有限公司 一种抑制或降解brd9的化合物及其组合物和药学上的应用
WO2023200800A1 (en) * 2022-04-11 2023-10-19 Foghorn Therapeutics Inc. Methods of treating androgen receptor-independent prostate cancer
WO2024163609A1 (en) * 2023-02-01 2024-08-08 Foghorn Therapeutics Inc. Compositions for treating cancer
KR20260029501A (ko) 2023-05-24 2026-03-04 베액티카 테라퓨틱스 아베 Tead에 대한 결합제로서의 방향족 아미드 및 이의 접합체
CN121816348A (zh) 2023-08-11 2026-04-07 深圳众格生物科技有限公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
CN117229202B (zh) * 2023-11-15 2024-01-26 苏州美诺医药科技有限公司 一种brd9靶向降解化合物的中间体的制备方法
WO2025256550A1 (zh) * 2024-06-12 2025-12-18 杭州中美华东制药有限公司 靶向降解剂配体及连接基的制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223452A1 (en) * 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
JP2018502097A (ja) * 2014-12-23 2018-01-25 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
JP2018507238A (ja) * 2015-03-05 2018-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブロモドメインｂｒｄ９の阻害剤としての新規ピリジノンおよびイソキノリノン
WO2018064589A1 (en) * 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
WO2018144649A1 (en) * 2017-01-31 2018-08-09 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2019099926A1 (en) * 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019121562A1 (en) * 2017-12-18 2019-06-27 F. Hoffmann-La Roche Ag Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety
WO2019140387A1 (en) * 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
JP2022523073A (ja) * 2019-01-29 2022-04-21 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3774808A1 (en) * 2018-03-26 2021-02-17 Novartis AG 3-hydroxy-n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives
CN111936498B (zh) * 2018-03-26 2024-04-16 诺华股份有限公司 N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
WO2020051235A1 (en) * 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
EP3917517A4 (en) * 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502097A (ja) * 2014-12-23 2018-01-25 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
JP2018507238A (ja) * 2015-03-05 2018-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブロモドメインｂｒｄ９の阻害剤としての新規ピリジノンおよびイソキノリノン
WO2017223452A1 (en) * 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
WO2018064589A1 (en) * 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
WO2018144649A1 (en) * 2017-01-31 2018-08-09 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2019099926A1 (en) * 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019121562A1 (en) * 2017-12-18 2019-06-27 F. Hoffmann-La Roche Ag Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety
WO2019140387A1 (en) * 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
JP2022523073A (ja) * 2019-01-29 2022-04-21 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOCHENKO, I. ET AL.: "Chemical Ligand Space of Cereblon", ACS OMEGA, vol. 3, no. 9, JPN6024035615, 2018, pages 11163 - 11171, ISSN: 0005625129 *
LU, JING ET AL.: "Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4", CHEMISTRY & BIOLOGY, vol. 22, no. 6, JPN6024035616, 2015, pages 755 - 763, ISSN: 0005625130 *
REMILLARD, D. ET AL.: "Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 56, no. 21, JPN6024035613, 2017, pages 5738 - 5743, ISSN: 0005625127 *
ZOPPI, V. ET AL.: "Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Ide", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, no. 2, JPN6024035614, 2019, pages 699 - 726, ISSN: 0005625128 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022547716A (ja) * 2019-09-16 2022-11-15 ノバルティス アーゲー 二機能性分解誘導薬及びそれらの使用方法
JP7785663B2 (ja) 2019-09-16 2025-12-15 ノバルティス アーゲー 二機能性分解誘導薬及びそれらの使用方法

Also Published As

Publication number Publication date
AU2020349451B2 (en) 2024-02-01
CN114641473A (zh) 2022-06-17
EP4041724A1 (en) 2022-08-17
KR20220063192A (ko) 2022-05-17
PY2054376A (es) 2021-09-07
PH12022550611A1 (en) 2023-03-13
BR112022003514A2 (pt) 2022-05-17
WO2021055295A1 (en) 2021-03-25
ECSP22018571A (es) 2022-04-29
US20220315578A1 (en) 2022-10-06
JOP20220069A1 (ar) 2023-01-30
AU2020349451A1 (en) 2022-04-21
MX2022003102A (es) 2022-04-06
PE20221417A1 (es) 2022-09-20
IL290677A (en) 2022-04-01
DOP2022000053A (es) 2023-01-31
CR20220105A (es) 2022-06-13
CO2022002842A2 (es) 2022-04-19
UY38880A (es) 2021-04-30
TW202123942A (zh) 2021-07-01
CA3153529A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
JP2022547952A (ja) Ｂｒｄ９二機能性分解誘導薬及びその使用方法
JP7811578B2 (ja) 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
CN105209448B (zh) 三环化合物及其用途
JP2022547716A (ja) 二機能性分解誘導薬及びそれらの使用方法
TW201524953A (zh) 治療活性化合物及其使用方法（二）
JP2025516367A (ja) Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体
CN112020496A (zh) 作为rho激酶抑制剂的苯并吡唑类化合物
CN115698023A (zh) 作为mcl-1抑制剂的大环2-氨基-3-氟-丁-3-烯酰胺
WO2008069242A1 (ja) 新規２環性複素環化合物
CN113698390B (zh) 用作ret激酶抑制剂的化合物及其应用
US20250236629A1 (en) Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses
CN114096546A (zh) 用作mcl-1抑制剂的大环螺环衍生物
JP2019521167A (ja) アミノピリジン誘導体およびそれらの選択的ａｌｋ−２阻害剤としての使用
KR20220113773A (ko) 사이클린 의존성 키나아제 9 억제제로서의 화합물 및 그의 용도
EP3983387B1 (en) Sulfonylurea derivatives and uses thereof
CN111683936B (zh) 多取代苯环化合物、制备方法及其用途
KR20180053357A (ko) 2,3,4,5-테트라히드로피리딘-6-아민 유도체
EP4061819A1 (en) Macrocyclic indole derivatives as mcl-1 inhibitors
WO2023093832A1 (zh) 三并环衍生物及其制备方法和应用
CN114728986A (zh) 作为mcl-1抑制剂的大环磺酰基衍生物
CN107428682A (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
TW201404772A (zh) 噁唑烷酮類衍生物、其製備方法及其在醫藥上的應用
CN116670141A (zh) 作为mcl-1抑制剂的大环支化3-氟-丁-3-烯酰胺
CN116710458A (zh) 作为mcl-1抑制剂的支链大环4-(吡唑-5-基)-吲哚衍生物
KR20260053336A (ko) Erk의 활성 조절을 위한 화합물 및 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251120

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260203